HIV

Mylan Laboratories has signed an agreement with Gilead Sciences to increase access to Tenofovir Alafenamide (TAF) based HIV treatments in developing countries.

Mylan received non-exclusive rights to manufacture and distribute TAF as both a single agent product and in combination with other drugs.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

According to the company, TAF is an investigational antiretroviral drug for the treatment of HIV-1 infection.

Mylan CEO Heather Bresch said: "Mylan’s mission is to provide the world’s seven billion people access to high quality medicines and set new standards in health care.

"By working with partners like Gilead to help ensure access to innovative new products such as Tenofovir Alafenamide (TAF) in the countries hardest hit by this disease, we can help stem the tide of HIV / AIDS around the world."

See Also:

"The deal allows Mylan to distribute TAF in 112 countries, providing treatment to 30 million HIV patients, representing 84% of those infected globally."

Mylan will receive technology transfer from Gilead following US Food and Drug Administration (FDA) approval for the drug, as part of the licensing agreement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The agreement enables the company to manufacture low-cost versions of TAF for developing markets, if approved as a single agent or in approved combinations containing TAF.

The deal allows Mylan to distribute TAF in 112 countries, providing treatment to 30 million HIV patients, representing 84% of those infected globally.

Mylan noted that Gilead’s Phase III trials met their primary objective, supporting the potential for TAF to provide a new treatment option for individuals living with HIV.

Image: Scanning electron micrograph of HIV-1 budding (in green) from cultured lymphocyte. Photo: courtesy of C. Goldsmith.